Edwards Lifesciences Prices $600 Million of Senior Notes

Edwards Lifesciences Prices $600 Million of Senior Notes 
IRVINE, CA -- (Marketwired) -- 09/24/13 --  Edwards Lifesciences
Corporation (NYSE: EW), the global leader in the science of heart
valves and hemodynamic monitoring, today announced that it has agreed
to sell $600 million aggregate principal amount of 2.875 percent
senior unsecured notes due Oct. 15, 2018 at a price equal to 99.498
percent of the principal. The sale of the senior notes is expected to
close on Oct. 3, 2013, subject to customary closing conditions. 
The company intends to use the net proceeds from the offering to
repay amounts outstanding under its revolving credit facility and any
remaining proceeds for general corporate purposes. The joint
book-running managers for the offering are Merrill Lynch, Pierce,
Fenner & Smith Incorporated, Goldman, Sachs & Co. and Morgan Stanley
& Co. LLC. 
The notes will be offered pursuant to an effective automatic shelf
registration statement on Form S-3 filed on Sept. 6, 2013, with the
Securities and Exchange Commission (the "SEC"). The terms and
conditions of the senior notes are set forth in a prospectus
supplement and the accompanying prospectus, which can be obtained
free of charge by visiting EDGAR on the SEC's website at
http://www.sec.gov, or by contacting Merrill Lynch, Pierce, Fenner &
Smith Incorporated, toll-free at (800) 294-1322; or Goldman, Sachs &
Co., toll-free at (866) 471-2526.  
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any state or other jurisdiction where such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction. 
About Edwards Lifesciences
 Edwards Lifesciences is the global leader
in the science of heart valves and hemodynamic monitoring. Driven by
a passion to help patients, the company partners with clinicians to
develop innovative technologies in the areas of structural heart
disease and critical care monitoring, enabling them to save and
enhance lives.  
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These statements include the
expected closing date and use of proceeds. Forward-looking statements
are based on estimates and assumptions made by management of the
company and are believed to be reasonable, though they are inherently
uncertain and difficult to predict. Our forward-looking statements
speak only as of the date on which they are made and we do not
undertake any obligation to update any forward-looking statement to
reflect events or circumstances after the date of the statement. 
Forward-looking statements involve risks and uncertainties that could
cause results to differ materially from those expressed or implied by
the forward-looking statements based on a number of factors,
including but not limited to, unexpected delays in the closing
process for the notes, unanticipated cash needs, and those risks
those detailed in the company's filings with the Securities and
Exchange Commission including its Annual Report on Form 10-K for the
year ended December 31, 2012. 
Edwards, Edwards Lifesciences and the stylized E logo are trademarks
of Edwards Lifesciences Corporation. 
Media Contact:  
Sarah Huoh
949-250-5070 
Investor Contact:  
David K. Erickson
949-250-6826 
Edwards Lifesciences Corporation
One Edwards Way 
Irvine, CA USA 92614 
Phone: 949.250.2500 
Fax: 949.250.2525